Shopping Cart 0
Cart Subtotal
AED 0

Aptevo Therapeutics Inc (APVO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company's only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and children with hemophilia B. Its pipeline includes immune-oncology candidates for the treatment metastatic castration-resistant prostate cancer, peripheral T-cell lymphoma (PTCL), hematological malignancies, psoriasis and inflammatory bowel disease, and solid tumors. Aptevo is also developing a lead bispecific antibody candidate in collaboration with Alligator Bioscience AB for the treatment of various types of cancer. The company's immuno-oncology candidates are built on its proprietary Adaptir platform. Aptevo is headquartered in Seattle, Washington, the US.

Aptevo Therapeutics Inc (APVO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10

Equity Offering 12

Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13

Asset Transactions 14

Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14

Aptevo Therapeutics Inc-Key Competitors 15

Aptevo Therapeutics Inc-Key Employees 16

Aptevo Therapeutics Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Recent Developments 18

Financial Announcements 18

Aug 20, 2018: Aptevo Therapeutics deploys Genedata Biologics to streamline Cancer Immunotherapy R&D 18

Aug 09, 2018: Aptevo Therapeutics reports second quarter 2018 financial results 19

May 10, 2018: Aptevo Therapeutics Reports First Quarter 2018 Financial Results 21

Mar 13, 2018: Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update 23

Nov 09, 2017: Aptevo Therapeutics Reports Third Quarter 2017 Financial Results 25

Aug 10, 2017: Aptevo Therapeutics Reports Second Quarter 2017 Financial Results 27

May 12, 2017: Aptevo Therapeutics Reports First Quarter 2017 Financial Results 28

Mar 31, 2017: Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update 30

Product News 32

Oct 02, 2017: Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit 32

Mar 14, 2017: Aptevo Therapeutics Expands Bispecific Antibody Portfolio 34

Clinical Trials 35

Mar 14, 2017: Aptevo Therapeutics Presents Preclinical Data on New Anti-CD123 ADAPTIR Bispecific Candidate APVO437 at the American Association for Cancer Research 2017 Annual Meeting 35

Other Significant Developments 36

Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aptevo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10

Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13

Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14

Aptevo Therapeutics Inc, Key Competitors 15

Aptevo Therapeutics Inc, Key Employees 16

Aptevo Therapeutics Inc, Other Locations 17

Aptevo Therapeutics Inc, Subsidiaries 17

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Aptevo Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Aptevo Therapeutics Inc (Aptevo), a subsidiary of Emergent Biosolutions Inc, is a biotechnology company that develops and commercializes oncology and hematology therapeutics. The company's only marketed product Ixinity that is indicated to replace the missing clotting factor IX in adults and children with hemophilia B. Its pipeline includes immune-oncology candidates for the treatment metastatic castration-resistant prostate cancer, peripheral T-cell lymphoma (PTCL), hematological malignancies, psoriasis and inflammatory bowel disease, and solid tumors. Aptevo is also developing a lead bispecific antibody candidate in collaboration with Alligator Bioscience AB for the treatment of various types of cancer. The company's immuno-oncology candidates are built on its proprietary Adaptir platform. Aptevo is headquartered in Seattle, Washington, the US.

Aptevo Therapeutics Inc (APVO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10

Equity Offering 12

Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13

Asset Transactions 14

Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14

Aptevo Therapeutics Inc-Key Competitors 15

Aptevo Therapeutics Inc-Key Employees 16

Aptevo Therapeutics Inc-Locations And Subsidiaries 17

Head Office 17

Other Locations & Subsidiaries 17

Recent Developments 18

Financial Announcements 18

Aug 20, 2018: Aptevo Therapeutics deploys Genedata Biologics to streamline Cancer Immunotherapy R&D 18

Aug 09, 2018: Aptevo Therapeutics reports second quarter 2018 financial results 19

May 10, 2018: Aptevo Therapeutics Reports First Quarter 2018 Financial Results 21

Mar 13, 2018: Aptevo Therapeutics Reports 2017 Financial Results and Provides Business Update 23

Nov 09, 2017: Aptevo Therapeutics Reports Third Quarter 2017 Financial Results 25

Aug 10, 2017: Aptevo Therapeutics Reports Second Quarter 2017 Financial Results 27

May 12, 2017: Aptevo Therapeutics Reports First Quarter 2017 Financial Results 28

Mar 31, 2017: Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update 30

Product News 32

Oct 02, 2017: Aptevo Therapeutics Presents New Data on Enhanced Features of Its Next Generation ADAPTIR Bispecific Platform at the World Bispecific Summit 32

Mar 14, 2017: Aptevo Therapeutics Expands Bispecific Antibody Portfolio 34

Clinical Trials 35

Mar 14, 2017: Aptevo Therapeutics Presents Preclinical Data on New Anti-CD123 ADAPTIR Bispecific Candidate APVO437 at the American Association for Cancer Research 2017 Annual Meeting 35

Other Significant Developments 36

Aug 29, 2017: ImmunoPrecise announces R&D success using the OmniAb platform to develop fully human antibodies 36

Appendix 37

Methodology 37

About GlobalData 37

Contact Us 37

Disclaimer 37


List Of Figure

List of Figures

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Aptevo Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8

Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Aptevo Therapeutics and Alligator Bioscience Enter into Co-Development Agreement 10

Aptevo Therapeutics Plans to Raise up to USD17.5 Million in Public Offering of Shares 12

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics 13

Saol Therapeutics Acquires Hyperimmune Products from Aptevo Therapeuticsuni for USD74.5 Million 14

Aptevo Therapeutics Inc, Key Competitors 15

Aptevo Therapeutics Inc, Key Employees 16

Aptevo Therapeutics Inc, Other Locations 17

Aptevo Therapeutics Inc, Subsidiaries 17

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Aptevo Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.